Frequently Asked Questions

Have questions about Smoflipid®? Get them answered below.

  • What is Smoflipid® ?
  • Smoflipid® is a lipid emulsion indicated for adults, that contains a blend of 4 different oils: 30% soybean oil, 30% olive oil, 25% Medium Chain Triglycerides, and 15% fish oil.
  • Does Smoflipid® contain enough essential fatty acids for patients?
  • Smoflipid® meets the essential fatty acid requirements of adult patients. It contains 35 mg/mL of linoleic acid and 4.5 mg/ml of α-linolenic acid.11
  • Can Smoflipid® be used for pediatric patients?
  • Smoflipid® is not indicated for pediatric patients. Smoflipid® is indicated in adult patients as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
  • Why is the omega 6-omega 3 fatty acid ratio in Smoflipid® significant?
  • Smoflipid® has a ratio of omega-6:omega-3 fatty acids of 2.5:1 that is in line with expert recommendations for intravenous lipid emulsions12-15. The omega-6:omega-3 fatty acid ratio in Smoflipid® has not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.
  • What is the dosage of Smoflipid® ?
  • Smoflipid® is for central or peripheral intravenous infusion. The usual daily dosage in adults is 1 to 2 grams/kg per day and should not exceed 2.5 grams/kg per day.
  • What additives are compatible with Smoflipid® ?
  • How can I order Smoflipid® ?
  • Orders can be placed direct by calling customer service at 1.888.386.1300 or by contacting your local Fresenius Kabi Sales Representative.
  • What is freeflex®?
  • freeflex® is an innovative bag designed for infusion solutions that Fresenius Kabi has marketed globally since 2005. The bag is made from multilayer polyolefin film that is non-PVC, non-DEHP, and not made with natural rubber latex. It is designed to help provide a simplified user experience.

References

  1. Smoflipid [prescribing information].
  2. Grimble RH. Fatty acid profile of modern lipid emulsions: scientific consideration for creating the ideal composition. Clin Nutr Suppl. 2005;1(3):9-15.
  3. Waitzberg DL, et al. New parenteral lipid emulsions for clinical use. JPEN J Parenter Enteral Nutr. 2006;30(4):351-367.
  4. Mayer K, et al. Fish oil in the critically ill: from experimental to clinical data. Curr Opin Clin Nutr Metab Care. 2006;9(2):140-148.
  5. Grimm H, et al. Immunonutrition-supplementary amino acids and fatty acids ameliorate immune deficiency in critically ill patients. Arch Surg. 2001;386(5):369-376.